ASH 2020
Virtual Scientific Program
Highlights of Accepted Novartis Data
**asciminib (ABL001)**

**Abstract # LBA-4 – Oral presentation**
December 8, 2020 | 8:15 am PST
Efficacy and Safety Results From ASCEMBL, a Multicenter, Open-label, Phase 3 Study of Asciminib vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloidn Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs)

**Abstract # 650 – Oral Presentation**
December 7, 2020 | 12:15 pm PST
Asciminib, a First-in-Class STAMP Inhibitor, Provides Durable Molecular Response in Patients (Pts) With Chronic Myeloid Leukemia (CML) Harboring the T315I Mutation: Primary Efficacy and Safety Results From a Phase 1 Trial

**Abstract # 3961 – Online Publication**
Structural and Biochemical Studies Confirming the Mechanism of Action of Asciminib, an Agent Specifically Targeting the ABL Myristoyl Pocket (STAMP)

**sabatolimab (MBG453)**

**Abstract # 657 – Oral Presentation**
December 7, 2020 | 12:30 pm PST
Efficacy and Safety of Sabatolimab (MBG453) in Combination With Hypomethylating Agents (HMAs) in Patients With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (HR-MDS): Updated Results From a Phase 1b Study

**Abstract # 2192 – Poster Presentation**
December 6, 2020 | 7:00 am PST
Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety by Dose

**Kymriah® (tisagenlecleucel)**

**Abstract # 1200 – Poster Presentation**
December 5, 2020 | 7:00 am PST
Ibrutinib Before Apheresis May Improve Tisagenlecleucel Manufacturing in Relapsed/Refractory Adult Diffuse Large B-Cell Lymphoma: Initial Results From a Phase Ib Study

**Abstract # 976 – Poster Presentation**
December 5, 2020 | 7:00 am PST
HESTER: A Phase II Study Evaluating Efficacy and Safety of Tisagenlecleucel Reinfusion in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia Experiencing Loss of B-Cell Aplasia
**Abstract # 1149 – Poster Presentation**  
December 5, 2020 | 7:00 am PST  
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 ELARA Trial

**Abstract # 1194 – Poster Presentation**  
December 5, 2020 | 7:00 am PST  
Myc Expression and Tumor-Infiltrating T Cells Are Associated With Response in Patients (Pts) With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated With Tisagenlecleucel in the JULIET Trial

---

**Adakveo® (crizanlizumab)**

**Abstract # 1715 – Poster Presentation**  
December 6, 2020 | 7:00 am PST  
Pharmacokinetics/Pharmacodynamics, Safety and Efficacy of Crizanlizumab in Patients With Sickle Cell Disease and a History of Vaso-Occlusive Crises: Results From the Phase II, Multicenter, Open-Label SOLACE-Adults Study

**Abstract # 796 – Poster Presentation**  
December 5, 2020 | 7:00 am PST  
The Effect of Crizanlizumab on the Number of Days Requiring Opioid Use for Management of Pain Associated With Vaso-Occlusive Crises in Patients With Sickle Cell Disease: Results From the SUSTAIN Trial

**Abstract # 17 – Oral Presentation**  
December 5, 2020 | 8:30 am PST  
Global Treatment Satisfaction Levels and Treatment Patterns From the International Sickle Cell World Assessment Survey (SWAY): Hydroxyurea (HU) Versus No HU

**Abstract # 801 – Poster Presentation**  
December 5, 2020 | 7:00 am PST  
An Age Analysis of the International Sickle Cell World Assessment Survey (SWAY), Focusing on Symptoms, Treatment Goals and the Impact of SCD on Patients’ Daily Lives

**Abstract # 808 – Poster Presentation**  
December 5, 2020 | 7:00 am PST  
Symptoms and Complications of Sickle Cell Disease Analyzed by Patient-Reported Genotype, Sex and Country/Region: Results From the International Sickle Cell World Assessment Survey (SWAY)
**Jakavi® (ruxolitinib)**

**Abstract # 77 – Oral Presentation**
December 5, 2020 | 8:00 am PST
Ruxolitinib vs Best Available Therapy in Patients With Steroid-Refractory/Steroid Dependent Chronic Graft-vs-Host Disease: Primary Findings From the Phase 3, Randomized REACH3 Study

**Abstract # 1519 – Poster Presentation**
December 5, 2020 | 7:00 am PST
Biomarker Analysis in Patients With Steroid-Refractory Acute Graft vs Host Disease Treated With Ruxolitinib or Best Available Therapy in the Randomized, Phase 3 REACH2 Study

**Abstract # 2440 – Poster Presentation**
December 6, 2020 | 7:00 am PST
Safety Analysis of Ruxolitinib (RUX) vs Best Available Therapy in Patients With Steroid-Refractory Acute Graft-vs-Host Disease in the Randomized Phase 3 REACH2 Study

**Abstract # 2997 – Poster Presentation**
December 7, 2020 | 7:00 am PST
ADORE: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients With Myelofibrosis

**Abstract # 2987 – Poster Presentation**
December 7, 2020 | 7:00 am PST
Long-Term Effect of Ruxolitinib (RUX) in Inadequately Controlled Polycythemia Vera (PV) Without Splenomegaly: 5-Year Results From the Phase 3 Response-2 Study

**Abstract # 1252 – Poster Presentation**
December 5, 2020 | 7:00 am PST
The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (Pts) With Myelofibrosis (MF) and Low Platelet (PLT) Counts (50 × 109/L to < 100 × 109/L) at Baseline

**Abstract # 2991 – Poster Presentation**
December 7, 2020 | 7:00 am PST
Interactions of Key Hematological Parameters With Red Cell Distribution Width (RDW) Are Associated With Incidence of Thromboembolic Events (TEs) in Polycythemia Vera (PV) Patients: A Machine Learning Study (PV-AIM)
**Promacta® (eltrombopag)**

Abstract # 2668 – Poster Presentation  
December 7, 2020 | 7:00 am PST  
Higher Symptom Burden in Patients With Immune Thrombocytopenia Experiencing Fatigue: Results From the ITP World Impact Survey (I-WISh)

---

**Abstract # 1760 – Poster Presentation**  
December 6, 2020 | 7:00 am PST  
A Patient’s Perspective on Impact of Immune Thrombocytopenia on Emotional Wellbeing: ITP World Impact Survey (I-WISh)

---

**Abstract # 845 – Poster Presentation**  
December 5, 2020 | 7:00 am PST  
Patients’ Reported Perceptions on Satisfaction With Immune Thrombocytopenia Treatments: Results From the ITP World Impact Survey (I-WISh)

---

**Rydapt® (midostaurin)**

Abstract # 632 – Poster Presentation  
December 7, 2020 | 11:30 am PST  
Phase 3b Study Assessing the Safety and Efficacy of Midostaurin in Younger and Older Patients with Newly Diagnosed, FLT3-Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for 7+3 or 5+2 Chemotherapy

---

**ianalumab (VAY736)**

Abstract # 1309 – Poster Presentation  
December 5, 2020 | 7:00 am PST  
Phase Ib Study of ianalumab (VAY736) and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL) on Ibrutinib Therapy